Jump to content

Enoblituzumab

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DMacks (talk | contribs) at 04:05, 22 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Enoblituzumab
Monoclonal antibody
Type?
SourceHumanized (from mouse)
TargetB7-H3
Clinical data
Other namesMGA271
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6474H9990N1726O2030S42
Molar mass145829.71 g·mol−1

Enoblituzumab is a monoclonal antibody designed for the treatment of cancer.[1] Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.

This drug was developed by MacroGenics, Inc.

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Enoblituzumab, American Medical Association.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Enoblituzumab&oldid=963845500"